Avalo Therap 
Welcome,         Profile    Billing    Logout  
 6 Products   7 Diseases  6 Products   4 Trials   226 News 
13 Trials

   

Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
camoteskimab (AVTX-007) / Apollo Therap
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Active, not recruiting
2
62
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
03/25
08/25
NCT04752371: A Study to Evaluate Camoteskimab in Participants With Still's Disease

Terminated
1b
5
Europe, US, RoW
Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Apollo Therapeutics Ltd
Adult Onset Still's Disease
05/22
05/22
quisovalimab (AVTX-002) / Avalo Therap
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
fasoracetam (NB-001) / Nobias Therap
NCT05290493: NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Completed
2
37
Canada, US
NB-001, fasoracetam monohydrate, (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one monohydrate, Placebo
Nobias Therapeutics, Inc.
22q11 Deletion Syndrome
06/23
06/23
D-galactose (AVTX-801) / Avalo Therap
AVTX-801, NCT05402332: Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG

Not yet recruiting
2
8
US
AVTX-801, D-Galactose, Placebo
Eva Morava-Kozicz, Children's Hospital of Philadelphia
PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation
12/25
12/25
NCT05402384: AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Not yet recruiting
2
10
US
AVTX-801, D-Galactose, Placebo
Eva Morava-Kozicz, National Institute of Neurological Disorders and Stroke (NINDS), Rare Diseases Clinical Research Network, Children's Hospital of Philadelphia
SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
03/28
03/28
L-fucose (AVTX-803) / Avalo Therap
NCT05462587: A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II

Recruiting
3
4
US
AVTX-803 (L-Fucose)
AUG Therapeutics
Leukocyte Adhesion Deficiency
11/24
11/24
NCT05754450: An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II

Recruiting
3
2
US
AVTX-803
AUG Therapeutics
Leukocyte Adhesion Deficiency
12/24
12/24
ES-481 / ES Therap
NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Recruiting
2a
24
RoW
ES-481, Placebo, Open-Label Extension Study
ES Therapeutics Australia Pty Ltd
Drug Resistant Epilepsy
12/23
12/23
NCT05234762: Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors

Recruiting
2a
24
Canada
ES-481, Placebo
ES Therapeutics Australia Pty Ltd
Tremor, Essential
12/23
12/23
ACTRN12621000033842: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.

Recruiting
2
24
 
ES Therapeutics Australia Pty Ltd, ES Therapeutics Australia Pty Ltd
Epilepsy
 
 
ACTRN12619001591145p: A Phase 1 study to evaluate safety and tolerability of ES-481 in healthy volunteers

Not yet recruiting
1
80
 
ES Therapeutics LLC, ES Therapeutics LLC
Epilepsy
 
 
ACTRN12619001591145: A Phase 1 study to evaluate safety and tolerability of ES-481 in healthy volunteers

Not yet recruiting
1
80
 
ES Therapeutics LLC, ES Therapeutics LLC
Epilepsy
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
camoteskimab (AVTX-007) / Apollo Therap
NCT06436183: A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

Active, not recruiting
2
62
Canada, US
Camoteskimab, APL-9109, AVTX-007, CERC-007, AEVI-007, MEDI2338, Placebo
Apollo Therapeutics Ltd
Atopic Dermatitis, Atopic, Dermatitis, Dermatologic Disease, Eczema, Eczema Atopic Dermatitis, Eczema, Atopic
03/25
08/25
NCT04752371: A Study to Evaluate Camoteskimab in Participants With Still's Disease

Terminated
1b
5
Europe, US, RoW
Camoteskimab (CERC-007, AVTX-007, AEVI-007)
Apollo Therapeutics Ltd
Adult Onset Still's Disease
05/22
05/22
quisovalimab (AVTX-002) / Avalo Therap
NCT05288504: A Study to Evaluate the Safety and Efficacy of AVTX-002 for the Treatment of Poorly Controlled Non-Eosinophilic Asthma.

Completed
2
91
US
AVTX-002, CERC-002, AEVI-002, MDGN-002, Placebo
Avalo Therapeutics, Inc.
Non-Eosinophilic Asthma
05/23
05/23
fasoracetam (NB-001) / Nobias Therap
NCT05290493: NB-001 in Children and Adolescents With 22q11 Deletion Syndrome

Completed
2
37
Canada, US
NB-001, fasoracetam monohydrate, (5R)-5-(piperidine-1-carbonyl)pyrrolidin-2-one monohydrate, Placebo
Nobias Therapeutics, Inc.
22q11 Deletion Syndrome
06/23
06/23
D-galactose (AVTX-801) / Avalo Therap
AVTX-801, NCT05402332: Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG

Not yet recruiting
2
8
US
AVTX-801, D-Galactose, Placebo
Eva Morava-Kozicz, Children's Hospital of Philadelphia
PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation
12/25
12/25
NCT05402384: AVTX-801 D-galactose Supplementation in SLC35A2-CDG

Not yet recruiting
2
10
US
AVTX-801, D-Galactose, Placebo
Eva Morava-Kozicz, National Institute of Neurological Disorders and Stroke (NINDS), Rare Diseases Clinical Research Network, Children's Hospital of Philadelphia
SLC35A2-CDG - Solute Carrier Family 35 Member A2 Congenital Disorder of Glycosylation
03/28
03/28
L-fucose (AVTX-803) / Avalo Therap
NCT05462587: A Study to Evaluate Efficacy and Safety of AVTX-803 in Patients with Leukocyte Adhesion Deficiency Type II

Recruiting
3
4
US
AVTX-803 (L-Fucose)
AUG Therapeutics
Leukocyte Adhesion Deficiency
11/24
11/24
NCT05754450: An Extension Study Assessing the Safety and Efficacy of AVTX-803 in Subjects with Leukocyte Adhesion Deficiency Type II

Recruiting
3
2
US
AVTX-803
AUG Therapeutics
Leukocyte Adhesion Deficiency
12/24
12/24
ES-481 / ES Therap
NCT04714996: Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients With Drug Resistant Epilepsy

Recruiting
2a
24
RoW
ES-481, Placebo, Open-Label Extension Study
ES Therapeutics Australia Pty Ltd
Drug Resistant Epilepsy
12/23
12/23
NCT05234762: Efficacy, Safety, and Pharmacokinetics of ES-481 in Adult Patients With Essential Tremors

Recruiting
2a
24
Canada
ES-481, Placebo
ES Therapeutics Australia Pty Ltd
Tremor, Essential
12/23
12/23
ACTRN12621000033842: A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ES-481 in Adult Patients with Drug Resistant Epilepsy.

Recruiting
2
24
 
ES Therapeutics Australia Pty Ltd, ES Therapeutics Australia Pty Ltd
Epilepsy
 
 
ACTRN12619001591145p: A Phase 1 study to evaluate safety and tolerability of ES-481 in healthy volunteers

Not yet recruiting
1
80
 
ES Therapeutics LLC, ES Therapeutics LLC
Epilepsy
 
 
ACTRN12619001591145: A Phase 1 study to evaluate safety and tolerability of ES-481 in healthy volunteers

Not yet recruiting
1
80
 
ES Therapeutics LLC, ES Therapeutics LLC
Epilepsy
 
 

Download Options